<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wavelet-Vermuse C</submitter><funding>NIH HHS</funding><pagination>3732</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9367339</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(15)</volume><pubmed_abstract>Cell division cycle 20 (CDC20) functions as a critical cell cycle regulator. It plays an important role in cancer development and drug resistance. However, the molecular mechanisms by which CDC20 regulates cellular drug response remain poorly understood. Chromatin-associated CDC20 interactome in breast cancer cells was analyzed by using affinity purification coupled with mass spectrometry. hnRNPU as a CDC20 binding partner was validated by co-immunoprecipitation and immunostaining. The molecular domain, comprising amino acid residues 461-653, on hnRNPU required for its interaction with CDC20 was identified by mapping of interactions. Co-immunoprecipitation showed that CDC20-mediated hnRNPU ubiquitination promotes its interaction with the CTCF and cohesin complex. The effects of CDC20-hnRNPU on nuclear size and chromatin condensation were investigated by analyzing DAPI and H2B-mCherry staining, respectively. The role of CDC20-hnRNPU in tumor progression and drug resistance was examined by CCK-8 cell survival and clonogenic assays. Our study indicates that CDC20-mediated ubiquitination of hnRNPU modulates chromatin condensation by regulating the interaction between hnRNPU and the CTCF-cohesin complex. Dysregulation of the CDC20-hnRNPU axis contributes to tumor progression and drug resistance.</pubmed_abstract><journal>Cancers</journal><pubmed_title>CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response.</pubmed_title><pmcid>PMC9367339</pmcid><funding_grant_id>CA202963</funding_grant_id><funding_grant_id>CA258765</funding_grant_id><funding_grant_id>CA202948</funding_grant_id><funding_grant_id>CA250110</funding_grant_id><funding_grant_id>CA258857</funding_grant_id><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Cristofanilli M</pubmed_authors><pubmed_authors>Wan Y</pubmed_authors><pubmed_authors>Odnokoz O</pubmed_authors><pubmed_authors>Wavelet-Vermuse C</pubmed_authors><pubmed_authors>Xue Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response.</name><description>Cell division cycle 20 (CDC20) functions as a critical cell cycle regulator. It plays an important role in cancer development and drug resistance. However, the molecular mechanisms by which CDC20 regulates cellular drug response remain poorly understood. Chromatin-associated CDC20 interactome in breast cancer cells was analyzed by using affinity purification coupled with mass spectrometry. hnRNPU as a CDC20 binding partner was validated by co-immunoprecipitation and immunostaining. The molecular domain, comprising amino acid residues 461-653, on hnRNPU required for its interaction with CDC20 was identified by mapping of interactions. Co-immunoprecipitation showed that CDC20-mediated hnRNPU ubiquitination promotes its interaction with the CTCF and cohesin complex. The effects of CDC20-hnRNPU on nuclear size and chromatin condensation were investigated by analyzing DAPI and H2B-mCherry staining, respectively. The role of CDC20-hnRNPU in tumor progression and drug resistance was examined by CCK-8 cell survival and clonogenic assays. Our study indicates that CDC20-mediated ubiquitination of hnRNPU modulates chromatin condensation by regulating the interaction between hnRNPU and the CTCF-cohesin complex. Dysregulation of the CDC20-hnRNPU axis contributes to tumor progression and drug resistance.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2025-04-04T10:44:04.23Z</modification><creation>2025-02-19T01:55:47.081Z</creation></dates><accession>S-EPMC9367339</accession><cross_references><pubmed>35954396</pubmed><doi>10.3390/cancers14153732</doi></cross_references></HashMap>